- Recommendation ID
- NG50/3
- Question
What is the clinical and cost effectiveness of non-selective beta-blockers for the primary prevention of decompensation in people with compensated cirrhosis and signs of clinically significant portal hypertension from non-invasive tests (such as tests to measure liver stiffness, or biomarkers)?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made this recommendation for research, see the rationale section on primary prevention of decompensation .
Full details of the evidence and the committee's discussion are in evidence review C: clinical and cost effectiveness of non-selective beta-blockers for the primary prevention of decompensation in people with compensated cirrhosis.
Source guidance details
- Comes from guidance
- Cirrhosis in over 16s: assessment and management
- Number
- NG50
- Date issued
- July 2016
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 11/01/2024 |